UK government bans export of lethal injection drugs to the USA

15 April 2011

The UK government will introduce additional controls on the export to the USA of drugs used in lethal injections and is calling on the European Union to follow its lead. The necessary order to extend the controls will be laid before Parliament in the coming days.

Measures will be put in place to stop the export to the USA of three drugs - pancuronium bromide, potassium chloride and sodium pentobarbital. The move builds on the government’s previous action in placing an emergency export control on sodium thiopental.

Business Secretary Vince Cable said: "We oppose the death penalty in all circumstances and are clear that British drugs should not be used to carry out lethal injections. That is why we introduced a control on sodium thiopental last year - the first of its kind in the world. And it is also why we are now controlling the export of the other drugs used in lethal injection in the USA.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical